Modality.AI: Revolutionizing Neurological and Psychiatric Assessment with Conversational AI

Modality.AI is a pioneering conversational AI platform founded in 2018 that transforms the way neurological and psychiatric conditions are assessed in clinical trials and patient care. By leveraging real-time analysis of speech, facial expressions, and motor function through an interactive virtual guide named 'Tina,' the platform enables accurate, objective, and scalable remote evaluations—eliminating the need for in-clinic visits, specialized devices, or clinical raters. Designed with scientific rigor and regulatory compliance, Modality.AI supports studies across over a dozen languages and dialects, integrates with global privacy standards like HIPAA and GDPR, and is FDA-listed as a Class II medical device. Its multimodal approach combines patient-reported experiences with behavioral data to deliver holistic digital biomarkers, accelerating drug development and improving diagnostic precision.

Key Features:

• Multimodal Assessment: Analyzes speech, facial expressions, and motor function during structured conversations.
• Virtual Guide 'Tina': A conversational AI that conducts real-time audiovisual dialog with patients.
• Remote & In-Clinic Flexibility: Supports both remote home-based assessments and in-clinic use via any web-enabled device.
• FDA-Class II Medical Device Status: Validated and registered under 21 CFR Part 820 and ISO 13485 standards.
• Clinically Validated Protocols: Grounded in peer-reviewed research for ALS, Parkinson’s, schizophrenia, depression, autism, and other CNS conditions.
• Patient Report of Problems™ (PROP™): Captures patients’ verbatim symptom descriptions, integrated with objective behavioral data.
• Real-Time, Explainable Results: Provides auditable, transparent insights for clinical decision-making and trial analysis.
• Multilingual Support: Operates in over a dozen languages and dialects, enabling global research inclusivity.
• Secure & Compliant Data Handling: HIPAA-compliant and GDPR-aligned; data encrypted in transit and at rest.
• Decentralized Clinical Trial Enablement: Facilitates remote digital phenotyping and patient-reported outcomes for distributed studies.
• Scientific Research Integration: Backed by 58+ publications and 21 patents, with collaborations across leading academic and clinical institutions.
• Partnership Ecosystem: Works with top biopharma companies, patient advocacy groups (e.g., EverythingALS), and research centers (e.g., Nathan Kline Institute, UCSF).

Pricing: Modality.AI offers a freemium model with demo access available and tailored pricing for enterprise and research partners based on project scope and scale.

Conclusion: Modality.AI stands at the forefront of AI-driven clinical innovation, delivering a powerful, ethical, and scientifically validated solution that enhances patient engagement, streamlines trials, and accelerates breakthroughs in neurology and psychiatry—making it an indispensable tool for modern medical research and patient-centered care.